Clinical trial
Efficacy, Safety, and Pharmacokinetics of Tirzepatide Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial
NCT07817875 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Efficacy, Safety, and Pharmacokinetics of Tirzepatide Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial
- Lead sponsor
- Eli Lilly and Company
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- September 25, 2026
- Completion date
- December 31, 2032
- Enrollment
- 150 (estimated)
- Sites
- 82
Conditions
As the registry lists them; a condition with its own page is linked.